|
Title
|
|
|
|
Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| High-risk neuroblastoma is a devastating malignancy with very limited therapeutic options. Here, we identify withaferin A (WA) as a natural ferroptosis-inducing agent in neuroblastoma, which acts through a novel double-edged mechanism. WA dose-dependently either activates the nuclear factorlike 2 pathway through targeting of Kelch-like ECH-associated protein 1 (noncanonical ferroptosis induction) or inactivates glutathione peroxidase 4 (canonical ferroptosis induction). Noncanonical ferroptosis induction is characterized by an increase in intracellular labile Fe(II) upon excessive activation of heme oxygenase-1, which is sufficient to induce ferroptosis. This double-edged mechanism might explain the superior efficacy of WA as compared with etoposide or cisplatin in killing a heterogeneous panel of high-risk neuroblastoma cells, and in suppressing the growth and relapse rate of neuroblastoma xenografts. Nano-targeting of WA allows systemic application and suppressed tumor growth due to an enhanced accumulation at the tumor site. Collectively, our data propose a novel therapeutic strategy to efficiently kill cancer cells by ferroptosis. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
The journal of clinical investigation. - New York, N.Y., 1924, currens
| |
|
Publication
|
|
|
|
New York, N.Y.
:
2018
| |
|
ISSN
|
|
|
|
0021-9738
[print]
1558-8238
[online]
| |
|
Volume/pages
|
|
|
|
128
:8
(2018)
, p. 3341-3355
| |
|
ISI
|
|
|
|
000440461500020
| |
|
Pubmed ID
|
|
|
|
29939160
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|